Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits

• Published in: Clinical chemistry and laboratory medicine Vol. 57; no. 12; pp. 1906 - 1914
• Main Authors: Laserna-Mendieta, Emilio J., Salvador-Martín, Sara, Arias-González, Laura, Ruiz-Ponce, Miriam, Menchén, Luis A., Sánchez, César, López-Fernández, Luis A., Lucendo, Alfredo J.
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 01.12.2019; Walter De Gruyter & Company
• Subjects: adalimumab; Adalimumab - analysis; Adalimumab - blood; Adolescent; Adult; Aged; Child; Child, Preschool; Classification; Correlation analysis; drug monitoring; Drug Monitoring - methods; ELISA; Enzyme Assays; Enzyme-linked immunosorbent assay; Enzyme-Linked Immunosorbent Assay - methods; Evaluation; Female; Gastrointestinal Agents - blood; Humans; Immunotherapy; Inflammatory bowel diseases; Inflammatory Bowel Diseases - drug therapy; Infliximab - blood; Intestine; Male; Methods; Middle Aged; Monoclonal antibodies; Mucosa; point-of-care testing; Quantitative analysis; Regression analysis; Serum levels; Spain; Statistical analysis; Statistical methods; TNF inhibitors; Variance analysis; Spain; point-of-care testing; inflammatory bowel diseases; adalimumab; drug monitoring; ELISA
• ISSN: 1434-6621; 1437-4331; 1437-4331
• DOI: 10.1515/cclm-2019-0202

Background Therapeutic drug monitoring (TDM) of adalimumab (ADA) in inflammatory bowel diseases (IBDs) has gained increased attention since several studies showed a correlation between drug levels and mucosal healing. The limitations of routine usage of enzyme-linked immunoabsorbent assay (ELISA) kits for measuring serum ADA concentrations have prompted the development of rapid methods, such as Quantum Blue (QB). We evaluated the interchangeability and agreement between the QB method and two established ELISA kits, Promonitor (PM) and Lisa-Tracker (LT). Methods Fifty samples from patients with IBD were included. Quantitative analysis was performed using the ANOVA test for repeated measures, Deming regression and the Bland-Altman plot. Clinical implications were evaluated by concordance in classifying patients into therapeutic windows according to the proposed cut-off levels for subtherapeutic (either <5 or <7.5 μg/mL) and supratherapeutic (>12 μg/mL) ranges. Results Statistical differences were detected between the QB method and the two ELISA kits, with QB overestimating ADA serum values compared to them. A lack of interchangeability was observed between methods, with greater differences as ADA levels increased. An analysis of a sub-set of samples with ADA values below 9 μg/mL (n = 25) showed that QB fulfilled the criteria to be interchangeable with the LT assay. Concordance for patient classification into ADA therapeutic windows was better for QB vs. LT than for QB vs. PM, with high agreement (>75%) for subtherapeutic levels among the three methods. Conclusions Although quantitative differences existed between the rapid method and ELISA kits that hampered their interchangeability, the agreement for identifying patients with subtherapeutic values of ADA was high.